Lyra Therapeutics Inc LYRA

NAS: LYRA | ISIN: US55234L1052 30/04/2025

0,119 USD (+0,68%)

(+0,68%) 30/04/2025

Grafiek Lyra Therapeutics Inc

Grafiek Lyra Therapeutics Inc

1 dag1d 0,68%
1 week1w 19,88%
1 maand1m -1,08%
3 maanden3m -34,83%
6 maanden6m -54,11%
1 jaar1j -97,74%
5 jaar5j -99,36%

Lyra Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

26 september 2023 · Thinking about buying stock in Gaucho Group Holdings, Lyra Therapeutics, Biophytis, Archer Aviation, or Femasys? · Persbericht

13 september 2022 · Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

13 september 2022 · Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study · Persbericht

10 september 2022 · LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting · Persbericht

8 september 2022 · Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients · Persbericht

6 september 2022 · Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022 · Persbericht

29 augustus 2022 · Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting · Persbericht

9 augustus 2022 · Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

5 juli 2022 · Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022 · Persbericht

5 juli 2022 · Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer · Persbericht

Profiel Lyra Therapeutics Inc

Gezondheidstechnologie

Productie van medische instrumenten

Werknemers: 71

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe